Evaluation of G2350A Polymorphism of the Angiotensin-Converting Enzyme (ACE) Gene in Chronic Kidney Disease

Abstract

Chronic kidney disease (CKD) becomes a major problem for world health. Numerous studies have documented that the polymorphisms in angiotensin-converting enzyme (ACE) gene may contribute to an individual risk for the loss of kidney function. The present study was undertaken to evaluate the possible relationship between ACE G2350A gene polymorphism and the risk of CKD in Uttar Pradesh population. A total of 379 (159 CKD patients and 220 healthy controls) subjects were recruited for this study. All subjects were genotyped for G2350A polymorphism by PCR-RFLP method. The significant differences were reported between CKD patients and control groups in height, BMI, WC, WH ratio, SBP, DBP, FBS, serum creatinine, eGFR, triglyceride, total cholesterol, HDL and LDL (p < 0.05); while there was no difference in weight, WC, HC and VLDL. The frequency of AA genotype and A-allele were significantly higher in healthy controls than to patients. Conclusively, this study showed that the G2350A polymorphism may not contribute to CKD risk. Further investigations are warranted in larger sample size to confirm our results.

Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM

“…Also, in ACE I/D polymorphism, the carriers of the I allele and A allele of ACE G2350A were more frequent in the diabetic patients than the control group. Furthermore, Verma et al 25 reported that patients with AA genotype were at lower risk for CKD in comparison with those with GG genotype. In current study, A-allele exhibited lower significant frequency in diabetic cases.…”